Pro-efferocytic nanoparticles are specifically taken up by lesional macrophages and prevent atherosclerosis
Source abstract
Abstract
Atherosclerosis is the process that underlies heart attack and stroke. A characteristic feature of the atherosclerotic plaque is the accumulation of apoptotic cells in the necrotic core. Prophagocytic antibody-based therapies are currently being explored to stimulate the phagocytic clearance of apoptotic cells; however, these therapies can cause off-target clearance of healthy tissues, which leads to toxicities such as anaemia. Here we developed a macrophage-specific nanotherapy based on single-walled carbon nanotubes loaded with a chemical inhibitor of the antiphagocytic CD47-SIRPα signalling axis. We demonstrate that these single-walled carbon nanotubes accumulate within the atherosclerotic plaque, reactivate lesional phagocytosis and reduce the plaque burden in atheroprone apolipoprotein-E-deficient mice without compromising safety, and thereby overcome a key translational barrier for this class of drugs. Single-cell RNA sequencing analysis reveals that prophagocytic single-walled carbon nanotubes decrease the expression of inflammatory genes linked to cytokine and chemokine pathways in lesional macrophages, which demonstrates the potential of 'Trojan horse' nanoparticles to prevent atherosclerotic cardiovascular disease.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Phagocytosis and Immune Regulation · Extracellular vesicles in disease · Immune cells in cancer
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (50)
Show source-provided references
1. Arandjelovic, S. & Ravichandran, K. S. Phagocytosis of apoptotic cells in homeostasis. Nat. Immunol. 16, 907–917 (2015).10.1038/ni.3253 ↗
2. Huynh, M. L., Fadok, V. A. & Henson, P. M. Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-β1 secretion and the resolution of inflammation. J. Clin. Invest. 109, 41–50 (2002).10.1172/JCI0211638 ↗
3. Yurdagul, A. Jr., Doran, A. C., Cai, B., Fredman, G. & Tabas, I. A. Mechanisms and consequences of defective efferocytosis in atherosclerosis. Front. Cardiovasc. Med. 4, 86 (2017).10.3389/fcvm.2017.00086 ↗
4. Jaiswal, S. et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138, 271–285 (2009).10.1016/j.cell.2009.05.046 ↗
5. Willingham, S. B. et al. The CD47-signal regulatory protein alpha (SIRPα) interaction is a therapeutic target for human solid tumors. Proc. Natl Acad. Sci. USA 109, 6662–6667 (2012).10.1073/pnas.1121623109 ↗
6. Kojima, Y. et al. CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature 536, 86–90 (2016).10.1038/nature18935 ↗
7. Leading Causes of Death, 1900–1998 (Centre for Disease Control and Prevention, 2015); https://www.cdc.gov/nchs/data/dvs/lead1900_98.pdf
8. Heron, M. & Anderson, R. N. Changes in the Leading Cause of Death: Recent Patterns in Heart Disease and Cancer Mortality (National Center for Health Statistics, 2016); https://www.cdc.gov/nchs/data/databriefs/db254.pdf
9. Brown, E. J. & Frazier, W. A. Integrin-associated protein (CD47) and its ligands. Trends Cell Biol. 11, 130–135 (2001).10.1016/S0962-8924(00)01906-1 ↗
10. Gresham, H. D. et al. Negative regulation of phagocytosis in murine macrophages by the Src kinase family member, Fgr. J. Exp. Med. 191, 515–528 (2000).10.1084/jem.191.3.515 ↗
11. Liu, J. et al. Pre-clinical development of a humanized Anti-CD47 antibody with anti-cancer therapeutic potential. PLoS ONE 10, e0137345 (2015).10.1371/journal.pone.0137345 ↗
12. Weiskopf, K. et al. Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies. Science 341, 88–91 (2013).10.1126/science.1238856 ↗
13. Liu, Z., Sun, X., Nakayama-Ratchford, N. & Dai, H. Supramolecular chemistry on water-soluble carbon nanotubes for drug loading and delivery. ACS Nano 1, 50–56 (2007).10.1021/nn700040t ↗
14. Schipper, M. L. et al. A pilot toxicology study of single-walled carbon nanotubes in a small sample of mice. Nat. Nanotechnol. 3, 216–221 (2008).10.1038/nnano.2008.68 ↗
15. Liu, Z. et al. Circulation and long-term fate of functionalized, biocompatible single-walled carbon nanotubes in mice probed by Raman spectroscopy. Proc. Natl Acad. Sci. USA 105, 1410–1415 (2008).10.1073/pnas.0707654105 ↗
16. Smith, B. R. et al. Selective uptake of single-walled carbon nanotubes by circulating monocytes for enhanced tumour delivery. Nat. Nanotechnol. 9, 481–487 (2014).10.1038/nnano.2014.62 ↗
17. Swirski, F. K. et al. Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J. Clin. Invest. 117, 195–205 (2007).10.1172/JCI29950 ↗
18. Robbins, C. S. et al. Extramedullary hematopoiesis generates Ly-6Chigh monocytes that infiltrate atherosclerotic lesions. Circulation 125, 364–374 (2012).10.1161/CIRCULATIONAHA.111.061986 ↗
19. Swirski, F. K. et al. Monocyte accumulation in mouse atherogenesis is progressive and proportional to extent of disease. Proc. Natl Acad. Sci. USA 103, 10340–10345 (2006).10.1073/pnas.0604260103 ↗
20. Moore, K. J. & Tabas, I. Macrophages in the pathogenesis of atherosclerosis. Cell 145, 341–355 (2011).10.1016/j.cell.2011.04.005 ↗
21. Liu, Z. et al. In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat. Nanotechnol. 2, 47–52 (2007).10.1038/nnano.2006.170 ↗
22. Campagnolo, L. et al. Biodistribution and toxicity of pegylated single wall carbon nanotubes in pregnant mice. Part. Fibre Toxicol. 10, 21 (2013).10.1186/1743-8977-10-21 ↗
23. Hung, S, C., Zhu, S., Ma, Z., Ghosen, E. & Mellins, E. D. Single-walled carbon nanotubes target neutrophils and Ly-6Chi monocytes and localize to joints in murine models of arthritis. J. Immunol. 175 (Suppl.), 23 (2018).
24. Daugherty, A., Manning, M. W. & Cassis, L. A. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J. Clin. Invest. 105, 1605–1612 (2000).10.1172/JCI7818 ↗
25. Zhang, Z., Shen, K., Lu, W. & Cole, P. A. The role of C-terminal tyrosine phosphorylation in the regulation of SHP-1 explored via expressed protein ligation. J. Biol. Chem. 278, 4668–4674 (2003).10.1074/jbc.M210028200 ↗
26. Schrijvers, D. M., De Meyer, G. R., Kockx, M. M., Herman, A. G. & Martinet, W. Phagocytosis of apoptotic cells by macrophages is impaired in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 25, 1256–1261 (2005).10.1161/01.ATV.0000166517.18801.a7 ↗
27. Poon, I. K., Lucas, C. D., Rossi, A. G. & Ravichandran, K. S. Apoptotic cell clearance: basic biology and therapeutic potential. Nat. Rev. Immunol. 14, 166–180 (2014).10.1038/nri3607 ↗
28. Rudd, J. H. et al. Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography: ready for prime time? J. Am. Coll. Cardiol. 55, 2527–2535 (2010).10.1016/j.jacc.2009.12.061 ↗
29. Luo, G. et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 386, 78–81 (1997).10.1038/386078a0 ↗
30. Carballo, E., Gilkeson, G. S. & Blackshear, P. J. Bone marrow transplantation reproduces the tristetraprolin-deficiency syndrome in recombination activating gene-2 (–/–) mice. Evidence that monocyte/macrophage progenitors may be responsible for TNFalpha overproduction. J. Clin. Invest. 100, 986–995 (1997).10.1172/JCI119649 ↗
31. Yoshimura, A., Naka, T. & Kubo, M. SOCS proteins, cytokine signalling and immune regulation. Nat. Rev. Immunol. 7, 454–465 (2007).10.1038/nri2093 ↗
32. Barker, R. N. et al. Antigen presentation by macrophages is enhanced by the uptake of necrotic, but not apoptotic, cells. Clin. Exp. Immunol. 127, 220–225 (2002).10.1046/j.1365-2249.2002.01774.x ↗
33. George, T. I. Automated Hematology Instrumentation (UptoDate Inc., 2018).
34. Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119–1131 (2017).10.1056/NEJMoa1707914 ↗
35. Advani, R. et al. CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin’s lymphoma. N. Engl. J. Med. 379, 1711–1721 (2018).10.1056/NEJMoa1807315 ↗
36. Plutzky, J., Neel, B. G. & Rosenberg, R. D. Isolation of a src homology 2-containing tyrosine phosphatase. Proc. Natl Acad. Sci. USA 89, 1123–1127 (1992).10.1073/pnas.89.3.1123 ↗
37. Green, M. C. & Shultz, L. D. Motheaten, an immunodeficient mutant of the mouse. I. Genetics and pathology. J. Hered. 66, 250–258 (1975).10.1093/oxfordjournals.jhered.a108625 ↗
38. Kojima, Y. et al. Cyclin-dependent kinase inhibitor 2B regulates efferocytosis and atherosclerosis. J. Clin. Invest. 124, 1083–1097 (2014).10.1172/JCI70391 ↗
39. Smith, B. R. & Gambhir, S. S. Nanomaterials for in vivo imaging. Chem. Rev. 117, 901–986 (2017).10.1021/acs.chemrev.6b00073 ↗
40. Flores, A. M. et al. Nanoparticle therapy for vascular diseases. Arterioscler. Thromb. Vasc. Biol. 39, 635–646 (2019).10.1161/ATVBAHA.118.311569 ↗
41. Alidori, S. et al. Targeted fibrillar nanocarbon RNAi treatment of acute kidney injury. Sci. Transl. Med. 8, 331ra339 (2016).10.1126/scitranslmed.aac9647 ↗
42. Kagan, V. E. et al. Carbon nanotubes degraded by neutrophil myeloperoxidase induce less pulmonary inflammation. Nat. Nanotechnol. 5, 354–359 (2010).10.1038/nnano.2010.44 ↗
43. Elgrabli, D. et al. Carbon nanotube degradation in macrophages: live nanoscale monitoring and understanding of biological pathway. ACS Nano 9, 10113–10124 (2015).10.1021/acsnano.5b03708 ↗
44. Green, D. R., Oguin, T. H. & Martinez, J. The clearance of dying cells: table for two. Cell Death Differ. 23, 915–926 (2016).10.1038/cdd.2015.172 ↗
45. Fredman, G. et al. Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice. Sci. Transl. Med. 7, 275ra220 (2015).
46. Liu, Z., Tabakman, S. M., Chen, Z. & Dai, H. Preparation of carbon nanotube bioconjugates for biomedical applications. Nat. Protocols 4, 1372–1382 (2009).10.1038/nprot.2009.146 ↗
47. Smith, B. R. et al. Shape matters: intravital microscopy reveals surprising geometrical dependence for nanoparticles in tumor models of extravasation. Nano Lett. 12, 3369–3377 (2012).10.1021/nl204175t ↗
48. Zheng, G. X. et al. Massively parallel digital transcriptional profiling of single cells. Nat. Commun. 8, 14049 (2017).
49. Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411–420 (2018).10.1038/nbt.4096 ↗
50. Ashburner, M. et al. Gene ontology: tool for the unification of biology. The gene ontology consortium. Nat. Genet. 25, 25–29 (2000).10.1038/75556 ↗